Becker ML - Search Results

1

The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.

de Keyser CE, Peters BJ, Becker ML, Visser LE, Uitterlinden AG, Klungel OH, Verstuyft C, Hofman A, Maitland-van der Zee AH, Stricker BH. de Keyser CE, et al. Among authors: becker ml. Pharmacogenet Genomics. 2014 Jan;24(1):43-51. doi: 10.1097/FPC.0000000000000018. Pharmacogenet Genomics. 2014. PMID: 24263182

2

Potential determinants of drug-drug interaction associated dispensing in community pharmacies.

Becker ML, Kallewaard M, Caspers PW, Schalekamp T, Stricker BH. Becker ML, et al. Drug Saf. 2005;28(5):371-8. doi: 10.2165/00002018-200528050-00001. Drug Saf. 2005. PMID: 15853439 Review.

3

Hospitalisations and emergency department visits due to drug-drug interactions: a literature review.

Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Becker ML, et al. Pharmacoepidemiol Drug Saf. 2007 Jun;16(6):641-51. doi: 10.1002/pds.1351. Pharmacoepidemiol Drug Saf. 2007. PMID: 17154346 Review.

4

Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.

Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RH, Stricker BH. Becker ML, et al. Clin Pharmacol Ther. 2008 Feb;83(2):288-92. doi: 10.1038/sj.clpt.6100273. Epub 2007 Jun 27. Clin Pharmacol Ther. 2008. PMID: 17597710

5

Increasing exposure to drug-drug interactions between 1992 and 2005 in people aged > or = 55 years.

Becker ML, Visser LE, van Gelder T, Hofman A, Stricker BH. Becker ML, et al. Drugs Aging. 2008;25(2):145-52. doi: 10.2165/00002512-200825020-00006. Drugs Aging. 2008. PMID: 18257601

6

Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea.

Becker ML, Aarnoudse AJ, Newton-Cheh C, Hofman A, Witteman JC, Uitterlinden AG, Visser LE, Stricker BH. Becker ML, et al. Pharmacogenet Genomics. 2008 Jul;18(7):591-7. doi: 10.1097/FPC.0b013e328300e8c5. Pharmacogenet Genomics. 2008. PMID: 18551039

7

Genetic variation in the NOS1AP gene is associated with the incidence of diabetes mellitus in users of calcium channel blockers.

Becker ML, Visser LE, Newton-Cheh C, Witteman JC, Hofman A, Uitterlinden AG, Stricker BH. Becker ML, et al. Diabetologia. 2008 Nov;51(11):2138-40. doi: 10.1007/s00125-008-1143-4. Epub 2008 Sep 3. Diabetologia. 2008. PMID: 18766325 No abstract available.

8

A common NOS1AP genetic polymorphism is associated with increased cardiovascular mortality in users of dihydropyridine calcium channel blockers.

Becker ML, Visser LE, Newton-Cheh C, Hofman A, Uitterlinden AG, Witteman JC, Stricker BH. Becker ML, et al. Br J Clin Pharmacol. 2009 Jan;67(1):61-7. doi: 10.1111/j.1365-2125.2008.03325.x. Epub 2008 Nov 17. Br J Clin Pharmacol. 2009. PMID: 19076153 Free PMC article.

9

Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study.

Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Becker ML, et al. Diabetes. 2009 Mar;58(3):745-9. doi: 10.2337/db08-1028. Epub 2009 Feb 19. Diabetes. 2009. PMID: 19228809 Free PMC article.

10

Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus.

Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Becker ML, et al. Pharmacogenomics J. 2009 Aug;9(4):242-7. doi: 10.1038/tpj.2009.15. Epub 2009 Apr 21. Pharmacogenomics J. 2009. PMID: 19381165

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

384 results

Search Page

Filters